Balthaser Kevin (CIK 1957554) reported 17 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-03-03). Recent activity: Buy ACRS (2,375 shares), Sell ACRS (677 shares), Buy ACRS (22,025 shares), Sell ACRS (6,449 shares), Buy ACRS (14,750 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-03 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Buy | 2,375 | $0 |
| 2026-03-03 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Sell | 677 | $1,943 |
| 2026-02-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Buy | 22,025 | $0 |
| 2026-02-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Sell | 6,449 | $22,378 |
| 2026-02-03 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Buy | 14,750 | $0 |
| 2026-02-03 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Sell | 4,984 | $17,494 |
| 2026-01-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Buy | 73,750 | $0 |
| 2026-01-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Sell | 19,934 | $60,001 |
| 2026-01-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Buy | 7,500 | $0 |
| 2026-01-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Sell | 2,250 | $6,772 |
| 2026-01-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Buy | 13,200 | $0 |
| 2026-01-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Sell | 4,461 | $12,848 |
| 2025-03-04 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Buy | 1,100 | $0 |
| 2025-03-04 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Buy | 2,375 | $0 |
| 2025-03-04 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Sell | 727 | $1,447 |
| 2025-02-04 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Buy | 14,750 | $0 |
| 2025-02-04 | Aclaris Therapeutics, Inc. (ACRS) | Chief Financial Officer | Sell | 5,816 | $14,424 |
Source: SEC Form 4 filings · as of 2026-03-03